BAL CRP may play a significant role in predicting the degree of inflammation in CF-ILD patients with mixed inflammatory and fibrotic phenotypes who may benefit from glucocorticoid and immunosuppressive therapy. The gene discussed is CRP; the disease is cystic fibrosis.